The Europe Hospital Acquired Infections Diagnostics Market was valued at USD 1.48 billion in 2024, and is projected to reach USD 1.61 billion by 2030, rising at a CAGR of 1.20%. In recent years, the prevalence of infections, particularly sepsis and surgical site infections, has driven a surge in demand for effective diagnostic solutions. In Europe, approximately 3.4 million sepsis cases occurred annually, leading to nearly 700,000 deaths each year, highlighting the urgent need for advanced diagnostic tools. The rising incidence of bloodstream infections (BSIs) compelled healthcare providers to implement robust diagnostic measures, presenting substantial market opportunities for companies specializing in hospital-acquired infection (HAI) diagnostics.
Technological advancements significantly contributed to market growth, with innovations in molecular diagnostics and rapid testing methods enhancing the accuracy and speed of HAI detection. These developments allowed for more timely identification, ultimately improving patient outcomes.
In addition, increasing healthcare expenditure across European countries facilitated the adoption of HAI diagnostics. Investments in healthcare infrastructure and proactive government initiatives aimed at infection control fostered a supportive environment for market expansion. Heightened patient awareness regarding HAIs further amplified the demand for effective diagnostic solutions, as informed patients and healthcare providers alike sought timely diagnostics, propelling market growth for innovative diagnostic products.
This product will be delivered within 1-3 business days.
Technological advancements significantly contributed to market growth, with innovations in molecular diagnostics and rapid testing methods enhancing the accuracy and speed of HAI detection. These developments allowed for more timely identification, ultimately improving patient outcomes.
In addition, increasing healthcare expenditure across European countries facilitated the adoption of HAI diagnostics. Investments in healthcare infrastructure and proactive government initiatives aimed at infection control fostered a supportive environment for market expansion. Heightened patient awareness regarding HAIs further amplified the demand for effective diagnostic solutions, as informed patients and healthcare providers alike sought timely diagnostics, propelling market growth for innovative diagnostic products.
Europe Hospital Acquired Infections Diagnostics Market Report Highlights
- Based on test type, the conventional tests dominated the market in 2024. Molecular tests, especially PCR-based methods, are projected to achieve the fastest CAGR of 1.5% during the forecast period, becoming essential for diagnosing hospital-acquired infections in Europe.
- Based on infection type, the UTI segment led the Europe hospital acquired infections diagnostics industry in 2024, accounting for a revenue share of 21.6% in 2024.
- In 2024, the consumables product segment captured the highest market share, driven by the need for accurate diagnosis, regulatory compliance, and high testing volumes in European hospitals.
- Based on type, the urinalysis segment is expected to grow lucratively due to rising UTI rates in hospitals, particularly in urology units, driven by high catheterization and demand for effective diagnostics.
- Key players operating in the market include BIOMÉRIEUX; Abbott; F. Hoffmann-La Roche Ltd; Siemens Healthineers AG; BD; HC Bioscience; QIAGEN; Thermo Fisher Scientific Inc.; Meridian Bioscience, Inc.; Hologic, Inc.
- In January 2025, BioMerieux announced its intent to pursue acquisitions with EUR 3bn- EUR 4bn available, enhancing its core segments within the diagnostics market.
This report addresses:
- Market intelligence to enable effective decision-making.
- Market estimates and forecasts from 2018 to 2030.
- Growth opportunities and trend analyses.
- Segment and regional revenue forecasts for market assessment.
- Competition strategy and market share analysis.
- Product innovation listings for you to stay ahead of the curve.
- COVID-19's impact and how to sustain in this fast-evolving market.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Europe Hospital Acquired Infections Diagnostics Market Variables, Trends, & Scope
Chapter 4. Europe Hospital Acquired Infections Diagnostics Market: Test Type Business Analysis
Chapter 5. Europe Hospital Acquired Infections Diagnostics Market: Infection Type Business Analysis
Chapter 6. Europe Hospital Acquired Infections Diagnostics Market: Product Business Analysis
Chapter 7. Europe Hospital Acquired Infections Diagnostics Market: Type Business Analysis
Chapter 8. Europe Hospital Acquired Infections Diagnostics Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies profiled in this Europe Hospital Acquired Infections Diagnostics market report include:- BIOMÉRIEUX
- Abbott
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- BD
- HC Bioscience
- QIAGEN
- Thermo Fisher Scientific Inc.
- Meridian Bioscience, Inc.
- Hologic, Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 100 |
Published | February 2025 |
Forecast Period | 2024 - 2030 |
Estimated Market Value ( USD | $ 1.48 Billion |
Forecasted Market Value ( USD | $ 1.61 Billion |
Compound Annual Growth Rate | 1.2% |
Regions Covered | Europe |
No. of Companies Mentioned | 10 |